Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings

Tommaso Schirinzi, Paola Imbriani, Alessio D'Elia, Giulia Di Lazzaro, Nicola Biagio Mercuri, Antonio Pisani

Research output: Contribution to journalArticlepeer-review


Objective To evaluate the efficacy of rotigotine in controlling the drooling of Parkinson's Disease (PD) patients. Patients and methods We assessed 7 PD patients (Hoehn and Yahr scale >2.5) with three different clinical scores (Drooling Severity and Frequency Scale − DSFS, Drooling Rating Scale – DRS and Sialorrhea Clinical Scale for PD – SCS) before and after 4 weeks of therapy. Statistical differences were analyzed with Wilcoxon signed-rank test. Results We observed that rotigotine significantly improves drooling as measured by the lowering of the three scores (p < 0.05). Conclusions Among non-motor symptoms of PD, drooling is one of the most embarrassing and disabling for patients. Current treatments are unsatisfactory and novel approaches are thus desirable. In this open-label pilot study we demonstrated on a small sample of patients that up to 4 mg/24 h of rotigotine, a non-ergolinic dopamine agonist with continuous transdermal delivery, may be helpful in the management of drooling in advanced PD.

Original languageEnglish
Pages (from-to)63-65
Number of pages3
JournalClinical Neurology and Neurosurgery
Publication statusPublished - May 1 2017


  • Deglutition and deglutition disorders
  • Drooling
  • Non motor symptoms
  • Parkinson's Disease
  • Rotigotine
  • Sialorrhea

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology


Dive into the research topics of 'Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings'. Together they form a unique fingerprint.

Cite this